TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03264482

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M-TURP
Description: endoscopic resection of the prostatic adenoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: THUVAP
Description: vaporization of prostatic adenoma via THULIUM laser
Study: NCT00882999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered via Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered via Injection
Study: NCT02985879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
Study: NCT02985879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
Study: NCT04079049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Oncological treatment in control group
Study: NCT00504803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell infusion
Description: Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
Study: NCT05333848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based storytelling programs with interactivity and stigma content
Description: Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based storytelling programs with stigma content only
Description: Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based storytelling programs with interactivity only
Description: Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Internet-based storytelling programs with no interactivity and no stigma content
Description: Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
Study: NCT00727519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01704937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube
Study: NCT00882999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered via Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered via Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via Injection
Study: NCT03483324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmanipulated Umbilical Cord Blood (UCB)
Description: Human leukocyte antigen (HLA) matched umbilical cord blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-110
Description: Expanded cord blood stem cells and engineered human endothelial cells
Study: NCT02020031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Study: NCT03077126

Intervention type: OTHER
Group type: OTHER
Intervention: Fleet Enema
Description: Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.

Intervention type: DEVICE
Group type: OTHER
Intervention: Aixplorer® ShearWave Elastography (SWE™)
Description: Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
Study: NCT00596206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: 20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: 20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
Study: NCT01726114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Optical Glucose Monitor™
Description: Test device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI blood glucose analyzer
Description: Reference device
Study: NCT01975194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
Study: NCT02470117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alginate-based reflux suppressant

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: magnesium-aluminium antacid gel
Study: NCT03077126

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pre-surgery Ultrasound
Description: The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostatectomy
Description: Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
Study: NCT01196624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid TMS, EXPOSURE TO TRAUMATIC STIMULI
Description: RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid TMS, EXPOSURE TO TRAUMATIC STIMULI
Description: RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid TMS, EXPOSURE TO TRAUMATIC STIMULI
Description: RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
Study: NCT03923231

Intervention type: DRUG
Intervention: Atazanavir 300mg/ Ritonavir 100 mg once daily
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care

Intervention type: DRUG
Intervention: Atazanavir 300mg/ Ritonavir 100 mg once daily
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care

Intervention type: DRUG
Intervention: Atazanavir 300mg/ Ritonavir 100 mg once daily
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care

Intervention type: DRUG
Intervention: Atazanavir 300mg/ Ritonavir 100 mg once daily
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care

Intervention type: DRUG
Intervention: Atazanavir 250 mg / ritonavir 80 mg
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg

Intervention type: DRUG
Intervention: Atazanavir 250 mg / ritonavir 80 mg
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
Study: NCT01019265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg
Description: Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
Study: NCT04013646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord blood infusion
Description: The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood infusion
Description: The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Study: NCT01019265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg
Description: Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
Study: NCT03185221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordimax
Description: One rapamycin eluting stent for treating the adapted coronary patients
Study: NCT01196624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid TMS, EXPOSURE TO TRAUMATIC STIMULI
Description: RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid TMS, EXPOSURE
Description: apid TMS, EXPOSURE
Study: NCT00304707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 300 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01196624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid TMS, EXPOSURE
Description: apid TMS, EXPOSURE
Study: NCT02000531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg oral dose of erlotinib given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg oral dose of erlotinib given once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
Study: NCT00348816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
Study: NCT03959449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation plus motor imagery
Description: Action observation (video) and motor imagery of running.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery
Description: Motor imagery of running

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus action Observation and motor imagery
Description: Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
Study: NCT01795222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
Study: NCT03050099

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
Study: NCT04013646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythropoietin injection
Description: Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo umbilical cord blood infusion
Description: Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Study: NCT01795222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
Study: NCT01591772

Intervention type: OTHER
Intervention: Neuroimaging & Neuropsychological Evaluation
Description: Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC

Intervention type: OTHER
Intervention: Neuroimaging & Neuropsychological Evaluation
Description: Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
Study: NCT04807543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-hydroxyprogesterone caproate
Description: intramuscular injection weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Castor Oil
Description: intramuscular injection weekly
Study: NCT00318903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (drug)
Description: 50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere (drug)
Description: Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy (procedure)
Description: Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy (procedure)
Description: After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
Study: NCT03586882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
Study: NCT00064129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT03815487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed 670G Insulin Pump in Auto Mode
Description: This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic MiniMed 670G Insulin Pump without Auto Mode
Description: Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
Study: NCT00348816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Radical prostatectomy as part of standard care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
Study: NCT00038831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
Study: NCT02171767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 - single rising dose
Study: NCT02581072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Applied topically once
Study: NCT03185221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V
Description: One everolimus eluting stent for treating the adapted coronary patients